Snurportin i human m3g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof
CA 2333895 A1 · Owner: Huls, Christoph · Inventors: Simandi, Claus; Luhrmann, Reinhard; Huber, Jochen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a novel polypeptide or a functional variant thereof acting as a 5'-2,2,7 terminal trymethylguanosine(m3G-)Cap-specific receptor of nucleus import in cells, to the production and to the use thereof. The invention is preferably used as a medicament or diagnostic reagent.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 7, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 7, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 7, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.